Stocktoria
RenovoRx, Inc. RNXT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-08-17
RenovoRx, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 70.9% | 100.0% | — | — | — |
| Operating margin | -1114.0% | -25511.6% | — | — | — |
| Net margin | -994.5% | -20497.7% | — | — | — |
| FCF margin | -977.3% | -21248.8% | — | — | — |
| Return on assets | -138.0% | -108.6% | -698.0% | -136.1% | -38.8% |
| Return on equity | -206.0% | -196.8% | -341.1% | -160.5% | -41.2% |
| Current ratio | 4.02 | 4.10 | 1.25 | 6.59 | 17.36 |
| Revenue growth | 2511.6% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001574094 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.